Longer duration of XXXX is associated with better outcome.

@entity1 @entity1892 @entity2905 @entity1252
OBJECTIVE: To report on the long-term follow-up, clinically and serologically, of 98 @entity1 with @entity1252 treated with @entity1892 ( @entity1892 ) over a 12 year period, focusing on the duration of the depletion. METHODS: A retrospective review of clinical and serological features of all @entity1252 @entity1 treated with @entity1892 from January 2000 until December 2012 in the Centre for Rheumatology, University College London Hospital. Clinical activity was assessed by the classic BILAG score at baseline and 6 and 12 months after the treatment. RESULTS: The period of depletion is extremely variable between @entity1 and within the same @entity1 on different occasions. The @entity1 were divided into two groups according to the duration of depletion and a defined threshold of 12 months was utilized. The group with longer duration of depletion was associated with a better outcome, with a decrease in BILAG score at 6 and 12 months. This group was also associated with @entity2905 present at any time during the course of the @entity1 's disease. No other clinical or serological feature was associated with longer duration of @entity1892 . CONCLUSION: Cycles of @entity1892 that induce longer duration of @entity1892 are associated with better outcome. @entity2905 may help to predict longer duration of the depletion and better outcome, although the mechanism is unclear.
